NYSE: BLCO · Industrial Applications and Services · 5 alerts · CIK 1860742
Share price
$20.88Close, Nov 16
Market cap
$7.46B
Shares outstanding
357.5MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Ophthalmic GoodsSIC 3851
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bausch & Lomb Corp filings on SEC EDGAR ↗
Bausch & Lomb SVP, Controller and CAO Frederick Munsch Sells $2.29M of Stock
Frederick Munsch, SVP, Controller and CAO, sold 112,015 shares of Bausch & Lomb Corp at $20.48 a share, worth $2.29M in total on Oct 29, 2026. Shares held after the trade: 45,831 (-71.0%).
Nathalie Bernier has resigned from the Board of Directors and the Science and Technology Committee of Bausch + Lomb Corporation, effective October 28, 2026. In connection with her departure, the company agreed to pay prorated cash compensation and accelerate the vesting of her 2026 restricted share unit awards. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Bausch + Lomb Corp filed its Q3 2026 Form 10-Q reporting 357,497,374 common shares outstanding as of October 21, 2026. The filing highlights significant macroeconomic risks including inflation, interest rate fluctuations, and the impact of U.S. trade tariffs, while continuing to plan for its eventual separation from Bausch Health Companies Inc.
Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion, representing 7% reported growth and 8% constant currency growth year-over-year. The company achieved GAAP net income of $32 million and raised its full-year 2026 guidance for both revenue and Adjusted EBITDA.
Term
Q3 2026
“Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability.”
Thomas J. Appio, chairman and interim CEO
“We have delivered against the commitments outlined at Investor Day for four consecutive quarters, and I believe there are additional opportunities to improve execution, enhance profitability and create even more value over time.”
Bausch + Lomb announced that CEO Brent Saunders has mutually agreed with the Board to depart the company and the Board effective October 12, 2026. Thomas J. Appio, the current Chairman of the Board and CEO of parent company Bausch Health, has been appointed interim CEO. In connection with his departure, Mr. Saunders will receive a $75.5 million lump-sum cash payment and forfeit all outstanding equity awards.